Current Report Filing (8-k)
March 16 2020 - 5:02PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): March 16, 2020
CORMEDIX INC.
(Exact name of registrant as specified
in its charter)
Delaware
|
|
001-34673
|
|
20-5894890
|
(State of other jurisdiction of
incorporation or organization)
|
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification No.)
|
400 Connell Drive, Suite 5000
Berkeley Heights, NJ
|
|
07922
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number,
including area code: (908) 517-9500
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2, below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Exchange
Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which
registered
|
Common stock, $0.001 par value
|
|
CRMD
|
|
NYSE American LLC
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02.
|
Results of Operations and Financial Condition
|
On March 16, 2020, CorMedix Inc. issued a press release announcing
its financial results for the fourth quarter and year ended December 31, 2019. A copy of the press release is furnished as Exhibit
99.1 to this report.
The information in this Item 2.02 (including Exhibit 99.1) shall
not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”)
or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the
Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01.
|
Financial Statements and Exhibits
|
(d) Exhibits
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
CORMEDIX INC.
|
|
|
|
Date: March 16, 2020
|
By:
|
/s/ Khoso Baluch
|
|
Name:
|
Khoso Baluch
|
|
Title:
|
Chief Executive Officer
|
2
CorMedix (AMEX:CRMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
CorMedix (AMEX:CRMD)
Historical Stock Chart
From Sep 2023 to Sep 2024